NEW YORK (GenomeWeb News) – Cancer genetics testing firm NeoGenomics today reported a 23 percent increase in revenues for the fourth quarter year over year.

For the three months ended Dec. 31, 2013, Ft. Meyers, Fla.-based NeoGenomics posted revenues of $18.3 million, compared to $14.9 million a year ago. Test volume was up 28 percent during the quarter, while average revenue per test slid 4 percent, NeoGenomics said.

The company had a profit of $857,000, or $.02 per share, compared to a net loss of $113,000, or breakeven on a per-share basis, a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.